Search

Your search keyword '"Reinholz, Monica"' showing total 119 results
Start Over Author "Reinholz, Monica"
119 results on '"Reinholz, Monica"'

1. Supplemental Information from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, primary, Dueck, Amylou C., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Riehle, Darren, primary, Jenkins, Robert B., primary, Geiger, Xochiquetzal J., primary, McCullough, Ann E., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

2. Data from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, primary, Dueck, Amylou C., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Riehle, Darren, primary, Jenkins, Robert B., primary, Geiger, Xochiquetzal J., primary, McCullough, Ann E., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figures 1 - 3, Tables 1 - 9 from Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Author

Reinholz, Monica M., primary, Kitzmann, Kathleen A., primary, Tenner, Kathleen, primary, Hillman, David, primary, Dueck, Amylou C., primary, Hobday, Timothy J., primary, Northfelt, Donald W., primary, Moreno-Aspitia, Alvaro, primary, Roy, Vivek, primary, LaPlant, Betsy, primary, Allred, Jake B., primary, Stella, Philip J., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

7. A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites

Author

Reinholz, Monica M., Zinnen, Shawn P., Dueck, Amylou C., Dingli, David, Reinholz, Gregory G., Jonart, Leslie A., Kitzmann, Kathleen A., Bruzek, Amy K., Negron, Vivian, Abdalla, Abdalla K., Arendt, Bonnie K., Croatt, Anthony J., Sanchez-Perez, Luis, Sebesta, David P., Lönnberg, Harri, Yoneda, Toshiyuki, Nath, Karl A., Jelinek, Diane F., Russell, Stephen J., Ingle, James N., Spelsberg, Thomas C., Dixon, Henry B.F. (Hal), Karpeisky, Alexander, and Lingle, Wilma L.

Published
2010
Full Text
View/download PDF

11. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Author

Perez, Edith A., Press, Michael F., Dueck, Amylou C., Jenkins, Robert B., Kim, Chungyeul, Chen, Beiyun, Villalobos, Ivonne, Paik, Soonmyung, Buyse, Marc, Wiktor, Anne E., Meyer, Reid, Finnigan, Melanie, Zujewski, JoAnne, Shing, Mona, Stern, Howard M., Lingle, Wilma L., Reinholz, Monica M., and Slamon, Dennis J.

Published
2013
Full Text
View/download PDF

13. Soluble Human Epidermal Growth Factor Receptor 2 (HER2) Levels in Patients With HER2-Positive Breast Cancer Receiving Chemotherapy With or Without Trastuzumab: Results From North Central Cancer Treatment Group Adjuvant Trial N9831

Author

Moreno-Aspitia, Alvaro, Hillman, David W., Dyar, Stephen H., Tenner, Kathleen S., Gralow, Julie, Kaufman, Peter A., Davidson, Nancy E., Lafky, Jacqueline M., Reinholz, Monica M., Lingle, Wilma L., Kutteh, Leila A., Carney, Walter P., Dueck, Amylou C., and Perez, Edith A.

Published
2013
Full Text
View/download PDF

17. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform

Author

Cunningham Julie M, Jenkins Robert B, Wickham-Garcia Eliza, April Craig S, Chen Beiyun, Dueck Amylou C, McCullough Ann E, Oberg Ann L, Zschunke Michael A, Asmann Yan W, Anderson S Keith, Eckel-Passow Jeanette E, Reinholz Monica M, Jen Jin, Perez Edith A, Fan Jian-Bing, and Lingle Wilma L

Subjects
Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panelv1 (1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors. Methods Bland-Altman plots and Spearman correlations evaluated intra/inter-panel agreement of normalized expression values. Unequal-variance t-statistics tested for differences in expression levels between HER2 + and HER2 - tumors. Regulatory network analysis was performed using Metacore (GeneGo Inc., St. Joseph, MI). Results Technical replicate correlations ranged between 0.815-0.956 and 0.986-0.997 for the 1.5K and 24K panels, respectively. Inter-panel correlations of expression values for the common 498 genes across the two panels ranged between 0.485-0.573. Inter-panel correlations of expression values of 17 probes with base-pair sequence matches between the 1.5K and 24K panels ranged between 0.652-0.899. In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). The top 52 discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor α (ESR1). Network analysis with a two-step extension also showed that the eight discriminating genes common to the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1. Conclusions The relative RNA abundance obtained from two highly differing density gene panels are correlated with eight common genes differentiating HER2 + and HER2 - breast tumors. Network analyses demonstrated biological consistency between the 1.5K and 24K gene panels.

Published
2010
Full Text
View/download PDF

21. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, additional, Dueck, Amylou C., additional, Tenner, Kathleen, additional, Ballman, Karla, additional, Riehle, Darren, additional, Jenkins, Robert B., additional, Geiger, Xochiquetzal J., additional, McCullough, Ann E., additional, and Perez, Edith A., additional

Published
2017
Full Text
View/download PDF

24. Next generation sequencing for DLBCL classification.

Author

Reinholz, Monica Madden, primary, Thompson, Debrah, additional, Botros, Ihab, additional, Sportmann, Paul, additional, Liu, Qian, additional, Roche, Pat, additional, Xu-Monette, Zijun, additional, Young, Ken H, additional, and LaFleur, Bonnie, additional

Published
2016
Full Text
View/download PDF

26. Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Author

Liu, Minetta C, primary, Rack, Brigitte, additional, Dueck, Amylou C, additional, Hillman, David W, additional, Campion, Michael B, additional, Reinholz, Monica M, additional, Halling, Kevin C, additional, Sotiriou, Christos, additional, Rothé, Françoise, additional, Maetens, Marion, additional, Rouas, Ghizlane, additional, Janni, Wolfgang, additional, Wolff, Antonio C, additional, Harris, Lyndsay N, additional, Gralow, Julie R, additional, Pritchard, Kathleen I, additional, Ellard, Susan, additional, Le-Lindqwister, Nguyet A, additional, Boyle, Frances, additional, De Azambuja, Evandro, additional, Piccart-Gebhart, Martine J, additional, Ignatiadis, Michail, additional, and Perez, Edith A, additional

Published
2015
Full Text
View/download PDF

27. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Author

Perez, Edith A., primary, Thompson, E. Aubrey, additional, Ballman, Karla V., additional, Anderson, S. Keith, additional, Asmann, Yan W., additional, Kalari, Krishna R., additional, Eckel-Passow, Jeanette E., additional, Dueck, Amylou C., additional, Tenner, Kathleen S., additional, Jen, Jin, additional, Fan, Jian-Bing, additional, Geiger, Xochiquetzal J., additional, McCullough, Ann E., additional, Chen, Beiyun, additional, Jenkins, Robert B., additional, Sledge, George W., additional, Winer, Eric P., additional, Gralow, Julie R., additional, and Reinholz, Monica M., additional

Published
2015
Full Text
View/download PDF

28. Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

Author

McCullough, Ann A.E., Dell'Orto, Patrizia, Reinholz, Monica, Gelber, Richard, Dueck, Amylou A.C., Russo, Leila, Jenkins, Robert R.B., Andrighetto, Stefania, Chen, Beiyun, Jackisch, Christian, Untch, Michael, Perez, Edith A, Piccart-Gebhart, Martine, Viale, Giuseppe, McCullough, Ann A.E., Dell'Orto, Patrizia, Reinholz, Monica, Gelber, Richard, Dueck, Amylou A.C., Russo, Leila, Jenkins, Robert R.B., Andrighetto, Stefania, Chen, Beiyun, Jackisch, Christian, Untch, Michael, Perez, Edith A, Piccart-Gebhart, Martine, and Viale, Giuseppe

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2014

29. International study on inter-reader variability for circulating tumor cells in breast cancer.

Author

Ignatiadis, Michail, Riethdorf, Sabine, Bidard, François-Clément, Vaucher, Isabelle, Khazour, Mustapha, Rothé, Françoise, Metallo, Jessica, Rouas, Ghizlane, Payne, Rachel E, Coombes, Raoul Charles, Teufel, Ingrid, Andergassen, Ulrich, Apostolaki, Stella, Politaki, Eleni, Mavroudis, Dimitris, Bessi, Silvia, Pestrin, Marta, Di Leo, Angelo, Campion, Michael, Reinholz, Monica, Perez, Edith A, Piccart-Gebhart, Martine, Borgen, E, Naume, Bjorn, Jiménez, José Antonio, Aura, Claudia Monica, Zorzino, Laura, Cassatella, Maria Cristina, Sandri, Maria Teresa, Mostert, Bianca, Sleijfer, Stefan, Kraan, Jaco, Janni, Wolfgang, Fehm, Tanja, Rack, B, Terstappen, LWMM, Repollet, Madeline, Pierga, Jean-Yves, Miller, Craig, Sotiriou, Christos, Michiels, Stefan, Pantel, Klaus, Ignatiadis, Michail, Riethdorf, Sabine, Bidard, François-Clément, Vaucher, Isabelle, Khazour, Mustapha, Rothé, Françoise, Metallo, Jessica, Rouas, Ghizlane, Payne, Rachel E, Coombes, Raoul Charles, Teufel, Ingrid, Andergassen, Ulrich, Apostolaki, Stella, Politaki, Eleni, Mavroudis, Dimitris, Bessi, Silvia, Pestrin, Marta, Di Leo, Angelo, Campion, Michael, Reinholz, Monica, Perez, Edith A, Piccart-Gebhart, Martine, Borgen, E, Naume, Bjorn, Jiménez, José Antonio, Aura, Claudia Monica, Zorzino, Laura, Cassatella, Maria Cristina, Sandri, Maria Teresa, Mostert, Bianca, Sleijfer, Stefan, Kraan, Jaco, Janni, Wolfgang, Fehm, Tanja, Rack, B, Terstappen, LWMM, Repollet, Madeline, Pierga, Jean-Yves, Miller, Craig, Sotiriou, Christos, Michiels, Stefan, and Pantel, Klaus

Abstract

Circulating tumor cells (CTCs) have been studied in breast cancer with the CellSearch(R) system. Given the low CTC counts in non-metastatic breast cancer, it is important to evaluate the inter-reader agreement., JOURNAL ARTICLE, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2014

30. Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial.

Author

San Antonio Breast Cancer Symposium – SABCS (December 12, 2014: San Antonio, Tx, USA), Liu, C, Rack, Brigitte, Dueck, Amylou A.C., Hillman, David D.W., Campion, M., Reinholz, Monica, Halling, KC, Sotiriou, Christos, Rothé, Françoise, Maetens, Marion M., Rouas, Ghizlane, Janni, Wolfgang, Wolff, Andrew A C A.A., Harris, L, Gralow, Julie R, Pritchard, Kathleen, Ellard, Sian, Le-Lindqwister, NA, Boyle, Frances, de Azambuja, Evandro, Piccart-Gebhart, Martine, Ignatiadis, Michail, Perez, E A, San Antonio Breast Cancer Symposium – SABCS (December 12, 2014: San Antonio, Tx, USA), Liu, C, Rack, Brigitte, Dueck, Amylou A.C., Hillman, David D.W., Campion, M., Reinholz, Monica, Halling, KC, Sotiriou, Christos, Rothé, Françoise, Maetens, Marion M., Rouas, Ghizlane, Janni, Wolfgang, Wolff, Andrew A C A.A., Harris, L, Gralow, Julie R, Pritchard, Kathleen, Ellard, Sian, Le-Lindqwister, NA, Boyle, Frances, de Azambuja, Evandro, Piccart-Gebhart, Martine, Ignatiadis, Michail, and Perez, E A

Abstract

info:eu-repo/semantics/nonPublished

Published
2014

31. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Author

Perez, Edith A., primary, Thompson, E. Aubrey, additional, Anderson, S. Keith, additional, Asmann, Yan W., additional, Kalari, Krishna R., additional, Eckel-Passow, Jeanette, additional, Dueck, Amylou C., additional, Tenner, Kathleen S., additional, Jen, Jin, additional, Fan, Jian-Bing, additional, Geiger, Xochiquetzal, additional, McCullough, Ann E., additional, Chen, Beiyun, additional, Zschunke, Michael, additional, Jenkins, Robert B., additional, Sledge, George W., additional, Winer, Eric P., additional, Gralow, Julie, additional, Reinholz, Monica Madden, additional, and Ballman, Karla V., additional

Published
2014
Full Text
View/download PDF

32. International study on inter-reader variability for circulating tumor cells in breast cancer

Author

Ignatiadis, Michail, primary, Riethdorf, Sabine, additional, Bidard, François-Clement, additional, Vaucher, Isabelle, additional, Khazour, Mustapha, additional, Rothé, Françoise, additional, Metallo, Jessica, additional, Rouas, Ghizlane, additional, Payne, Rachel E, additional, Coombes, Raoul Charles, additional, Teufel, Ingrid, additional, Andergassen, Ulrich, additional, Apostolaki, Stella, additional, Politaki, Eleni, additional, Mavroudis, Dimitris, additional, Bessi, Silvia, additional, Pestrin, Marta, additional, Di Leo, Angelo, additional, Campion, Michael, additional, Reinholz, Monica, additional, Perez, Edith, additional, Piccart, Martine, additional, Borgen, Elin, additional, Naume, Bjorn, additional, Jimenez, Jose, additional, Aura, Claudia Monica, additional, Zorzino, Laura, additional, Cassatella, Maria Cristina, additional, Sandri, Maria Teresa, additional, Mostert, Bianca, additional, Sleijfer, Stefan, additional, Kraan, Jaco, additional, Janni, Wolfgang, additional, Fehm, Tanja, additional, Rack, Brigitte, additional, Terstappen, Leon, additional, Repollet, Madeline, additional, Pierga, Jean-Yves, additional, Miller, Craig, additional, Sotiriou, Christos, additional, Michiels, Stefan, additional, and Pantel, Klaus, additional

Published
2014
Full Text
View/download PDF

33. Minimal residual disease and circulating tumor cells in breast cancer

Author

Ignatiadis, Michail, Reinholz, Monica, Ignatiadis, Michail, and Reinholz, Monica

Abstract

Tumor cell dissemination in bone marrow or other organs is thought to represent an important step in the metastatic process. The detection of bone marrow disseminated tumor cells is associated with worse outcome in early breast cancer. Moreover, the detection of peripheral blood circulating tumor cells is an adverse prognostic factor in metastatic breast cancer, and emerging data suggest that this is also true for early disease. Beyond enumeration, the characterization of these cells has the potential to improve risk assessment, treatment selection and monitoring, and the development of novel therapeutic agents, and to advance our understanding of the biology of metastasis. © 2011 BioMed Central Ltd., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2011

34. Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., additional, Geiger, Xochiquetzal J., additional, Tenner, Kathleen, additional, Ballman, Karla, additional, Jenkins, Robert B., additional, Riehle, Darren, additional, Chen, Beiyun, additional, McCullough, Ann E., additional, Davidson, Nancy E., additional, Martino, Silvana, additional, Sledge, George W., additional, Kaufman, Peter A., additional, Kutteh, Leila A., additional, Gralow, Julie, additional, Harris, Lyndsay N., additional, Ingle, James N., additional, Lingle, Wilma L., additional, and Perez, Edith A., additional

Published
2013
Full Text
View/download PDF

35. Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial

Author

Perez, Edith A., primary, Dueck, Amylou C., additional, McCullough, Ann E., additional, Chen, Beiyun, additional, Geiger, Xochiquetzal J., additional, Jenkins, Robert B., additional, Lingle, Wilma L., additional, Davidson, Nancy E., additional, Martino, Silvana, additional, Kaufman, Peter A., additional, Kutteh, Leila A., additional, Sledge, George W., additional, Harris, Lyndsay N., additional, Gralow, Julie R., additional, and Reinholz, Monica M., additional

Published
2013
Full Text
View/download PDF

37. Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer (N1031, Alliance).

Author

Sideras, Kostandinos, primary, Moreno-Aspitia, Alvaro, additional, Tenglin, Richard Charles, additional, Liu, Heshan, additional, Lingle, Wilma L., additional, Reinholz, Monica Madden, additional, Halling, Kevin C, additional, Chen, Beiyun, additional, Gross, Gerald G., additional, Mowat, Rex Bradford, additional, Dakhil, Shaker R., additional, and Perez, Edith A., additional

Published
2012
Full Text
View/download PDF

38. Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

Author

Perez, Edith A., primary, Dueck, Amylou C., additional, McCullough, Ann E., additional, Reinholz, Monica M., additional, Tenner, Kathleen S., additional, Davidson, Nancy E., additional, Gralow, Julie, additional, Harris, Lyndsay N., additional, Kutteh, Leila A., additional, Hillman, David W., additional, Jenkins, Robert B., additional, and Chen, Beiyun, additional

Published
2011
Full Text
View/download PDF

39. Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Author

Reinholz, Monica M., primary, Kitzmann, Kathleen A., additional, Tenner, Kathleen, additional, Hillman, David, additional, Dueck, Amylou C., additional, Hobday, Timothy J., additional, Northfelt, Donald W., additional, Moreno-Aspitia, Alvaro, additional, Roy, Vivek, additional, LaPlant, Betsy, additional, Allred, Jake B., additional, Stella, Philip J., additional, Lingle, Wilma L., additional, and Perez, Edith A., additional

Published
2011
Full Text
View/download PDF

41. C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

Author

Perez, Edith A., primary, Jenkins, Robert B., additional, Dueck, Amylou C., additional, Wiktor, Anne E., additional, Bedroske, Patrick P., additional, Anderson, S. Keith, additional, Ketterling, Rhett P., additional, Sukov, William R., additional, Kanehira, Kazunori, additional, Chen, Beiyun, additional, Geiger, Xochiquetzal J., additional, Andorfer, Cathy A., additional, McCullough, Ann E., additional, Davidson, Nancy E., additional, Martino, Silvana, additional, Sledge, George W., additional, Kaufman, Peter A., additional, Kutteh, Leila A., additional, Gralow, Julie R., additional, Harris, Lyndsay N., additional, Ingle, James N., additional, Lingle, Wilma L., additional, and Reinholz, Monica M., additional

Published
2011
Full Text
View/download PDF

42. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL®platform

Author

Reinholz, Monica M, primary, Eckel-Passow, Jeanette E, additional, Anderson, S Keith, additional, Asmann, Yan W, additional, Zschunke, Michael A, additional, Oberg, Ann L, additional, McCullough, Ann E, additional, Dueck, Amylou C, additional, Chen, Beiyun, additional, April, Craig S, additional, Wickham-Garcia, Eliza, additional, Jenkins, Robert B, additional, Cunningham, Julie M, additional, Jen, Jin, additional, Perez, Edith A, additional, Fan, Jian-Bing, additional, and Lingle, Wilma L, additional

Published
2010
Full Text
View/download PDF

43. HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Author

Perez, Edith A., primary, Reinholz, Monica M., additional, Hillman, David W., additional, Tenner, Kathleen S., additional, Schroeder, Matthew J., additional, Davidson, Nancy E., additional, Martino, Silvana, additional, Sledge, George W., additional, Harris, Lyndsay N., additional, Gralow, Julie R., additional, Dueck, Amylou C., additional, Ketterling, Rhett P., additional, Ingle, James N., additional, Lingle, Wilma L., additional, Kaufman, Peter A., additional, Visscher, Daniel W., additional, and Jenkins, Robert B., additional

Published
2010
Full Text
View/download PDF

44. Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay

Author

Huang, Weidong, primary, Reinholz, Monica, additional, Weidler, Jodi, additional, Yolanda, Lie, additional, Paquet, Agnes, additional, Whitcomb, Jeannette, additional, Lingle, Wilma, additional, Jenkins, Robert B., additional, Chen, Beiyun, additional, Larson, Jeffrey S., additional, Tan, Yuping, additional, Sherwood, Thomas, additional, Bates, Michael, additional, and Perez, Edith A., additional

Published
2010
Full Text
View/download PDF

45. Molecular Detection of Circulating Cancer Cells for Early Diagnosis of Breast Cancer

Author

MAYO CLINIC ROCHESTER MN, Reinholz, Monica M., Roche, Patrick C., MAYO CLINIC ROCHESTER MN, Reinholz, Monica M., and Roche, Patrick C.

Abstract

Early detection is the most significant means for reducing the morbidity and mortality due to breast cancer. in addition to mammography and physical examination, sensitive molecular techniques may also be used to detect early stage breast cancer. Evidence suggests that breast cancer cells are released into the circulation at an early stage of the disease (1). A recent study reported that 95% of early stage breast cancer patients had circulating cells that could be detected immunohistochemically with a nonspecific epithelial antibody (2). In addition, mammaglobin, the most breast-specific gene known, was detected in circulating tumor cells in the blood from 20 of 32 metastatic breast cancer patients (3). These intriguing results clearly demand validation with studies that can sensitively and specifically detect circulating breast cancer cells. We hypothesize that sensitive molecular detection of cancer cells in peripheral blood using novel breast-specific genes will provide a screening test that can be used independently or in concert with mammography and physical examination to more accurately detect early stage breast cancer.

Published
2002

47. Molecular Detection of Circulating Cancer Cells for Early Diagnosis of Breast Cancer

Author

MAYO CLINIC ROCHESTER MN, Reinholz, Monica M., Roche, Patrick C., MAYO CLINIC ROCHESTER MN, Reinholz, Monica M., and Roche, Patrick C.

Abstract

Goal: The goal of this project is to detect circulating cancer cells using breast-specific tumor markers in the blood from 200 patients who have suspicious mammograms and breast tissue biopsies. These molecular detection results will be correlated with the biopsy results. Patient accrual: Because this study just recently opened in July, 2001, we have collected blood from 54 patients with suspicious mammograms immediately prior to a breast tissue biopsy. These patients were informed of the investigational aspects of this study and have given written consent in accordance with institutional and federal guidelines. Molecular detection progress: Isolation of mononuclear cells by density gradient centrifugation and immunomagnetic capture of epithelial cells from all the collected blood samples have been performed. Isolation and reverse transcription of mRNA from each accrued sample are currently in progress. After reverse transcription, cDNA from each sample will be amplified using fluorescent-based kinetic PCR with gene-specific primers. Circulating cancer cells will be detected using mammaglobin, B305D, and B726P, which are breast-specific genes, and gamma-aminobutyrate type A receptor it subunit, cytokeratin-1 9, and beta-actin. Summary: We have collected 25% of the proposed 200 sample accrual, and the molecular detection of circulating cancer cells from the collected samples is in progress.

Published
2001

48. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Author

Gilbert, Judith A., primary, Goetz, Matthew P., additional, Reynolds, Carol A., additional, Ingle, James N., additional, Giordano, Karin F., additional, Suman, Vera J., additional, Blair, Hilary E., additional, Jenkins, Robert B., additional, Lingle, Wilma L., additional, Reinholz, Monica M., additional, Adjei, Alex A., additional, and Ames, Matthew M., additional

Published
2008
Full Text
View/download PDF

50. Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay.

Author

Weidong Huang, Reinholz, Monica, Weidler, Jodi, Lie, Yolanda, Paquet, Agnes, Whitcomb, Jeannette, Lingle, Wilma, Jenkins, Robert B., Beiyun Chen, Larson, Jeffrey S., Yuping Tan, Sherwood, Thomas, Bates, Michael, and Perez, Edith A.

Subjects
*IMMUNOHISTOCHEMISTRY, *IN situ hybridization, *HER2 gene, *GENE expression, *GENETIC regulation
Abstract

The accuracy and reliability of immunohistochemical analysis and in situ hybridization for the assessment of HER2 status remains a subject of debate. We developed a novel assay (HERmark Breast Cancer Assay, Monogram Biosciences, South San Francisco, CA) that provides precise quantification of total HER2 protein expression (H2T) and HER2 homodimers (H2D) in formalin-fixed, paraffinembedded tissue specimens. H2T and H2D results of 237 breast cancers were compared with those of immunohistochemical studies and fluorescence in situ hybridization (FISH) centrally performed at the Mayo Clinic, Rochester, MN. H2T described a continuum across a wide dynamic range (~2.5 log). Excluding the equivocal cases, HERmark showed 98% concordance with immunohistochemical studies for positive and negative assay values. For the 94 immunohistochemically equivocal cases, 67% and 39% concordance values were observed between HERmark and FISH for positive and negative assay values, respectively. Polysomy 17 in the absence of HER2 gene amplification did not result in HER2 overexpression as evaluated quantitatively using the HERmark assay. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results